X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MB22001 (lysergic acid diethylamide) in its microdosed proprietary titratable form is being developed in phase 2 clinical trials for the treatment of major depressive disorder.
Lead Product(s): LSD
Therapeutic Area: Psychiatry/Psychology Product Name: MB22001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2024
Details:
MindBio will seek to advance a drug candidate EB-002 (Psilocin Prodrug). Currently, it is being evaluated in the early-stage clinical trials studies for the treatment of depression, anxiety.
Lead Product(s): Psilocin Prodrug
Therapeutic Area: Psychiatry/Psychology Product Name: EB-002
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Enveric Biosciences
Deal Size: $66.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 14, 2024
Details:
MB22001 (lysergic acid diethylamide) in its microdosed proprietary titratable form is being developed in phase 2 clinical trials for the treatment of major depressive disorder.
Lead Product(s): LSD
Therapeutic Area: Psychiatry/Psychology Product Name: MB22001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
MB22001 (lysergic acid diethylamide) in its microdosed proprietary titratable form is being developed in phase 2 clinical trials for the treatment of major depressive disorder.
Lead Product(s): LSD
Therapeutic Area: Psychiatry/Psychology Product Name: MB22001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
MB22001 (lysergic acid diethylamide) in its microdosed proprietary titratable form is being developed in phase 2 clinical trials for the treatment of major depressive disorder.
Lead Product(s): LSD
Therapeutic Area: Psychiatry/Psychology Product Name: MB22001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
MB22001 (Lysergic acid diethylamide) is titratable form of LSD for take-home microdosing. It is being evaluated in phase 2 clinical trials for the treatment of Major Depressive Disorder.
Lead Product(s): LSD
Therapeutic Area: Psychiatry/Psychology Product Name: MB22001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
MB22001 (lysergic acid diethylamide) is a 5-HT2 receptor inhibitor, small molecule drug candidate. It is being evaluated for the treatment of depression in cancer patients.
Lead Product(s): LSD
Therapeutic Area: Psychiatry/Psychology Product Name: MB22001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2023
Details:
MB22001 is a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for safe and effective take home microdosing in patients suffering from Major Depressive Disorder.
Lead Product(s): LSD
Therapeutic Area: Psychiatry/Psychology Product Name: MB22001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2023
Details:
MB22001 is a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for safe and effective take home microdosing in patients suffering from Major Depressive Disorder.
Lead Product(s): LSD
Therapeutic Area: Psychiatry/Psychology Product Name: MB22001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2023
Details:
Lysergic Acid Diethylamide is a potent psychoactive substance which binds to the 5-HT2A receptor as a partial agonist and 5-HT1A as an agonist. It is being investigated for major depressive disorder.
Lead Product(s): LSD
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
